Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY2862789 in Advanced Solid Tumors
NCT05858164Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of pasodacigib in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Bayer. Primary endpoints: Treatment-Emergent Adverse Events at 90 days, Dose-Limiting Toxicities at 21 days and 5 more. Started Aug 2023; status: completed.
02
Drugs
pasodacigib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05858164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05858164.